Global Biologics Contract Manufacturing Market Size & Outlook

The global biologics contract manufacturing market size was estimated at USD 31,922.5 million in 2024 and is projected to reach USD 57,589.2 million by 2030, growing at a CAGR of 10.3% from 2025 to 2030.
Revenue, 2024 (US$M)
$31,922.5
Forecast, 2030 (US$M)
$57,589.2
CAGR, 2025 - 2030
10.3%
Report Coverage
Worldwide

Global biologics contract manufacturing market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Related Markets

Global biologics contract manufacturing market highlights

  • The global biologics contract manufacturing market generated a revenue of USD 31,922.5 million in 2024 and is expected to reach USD 57,589.2 million by 2030.
  • The market is expected to grow at a CAGR (2025 - 2030) of 10.3% by 2030.
  • In terms of segment, monoclonal antibodies (mabs) accounted for a revenue of USD 18,487.2 million in 2024.
  • Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
  • In terms of region, North America was the largest revenue generating market in 2024.
  • Country-wise, China is expected to register the highest CAGR from 2025 to 2030.

Global data book summary

Market revenue in 2024USD 31,922.5 million
Market revenue in 2030USD 57,589.2 million
Growth rate10.3% (CAGR from 2025 to 2030)
Largest segmentMonoclonal antibodies (mabs)
Fastest growing segmentVaccines
Historical data covered2018 - 2023
Base year for estimation2024
Forecast period covered2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationVaccines, Monoclonal Antibodies (mAbs), Recombinant Protein, Antisense, RNAi, & Molecular Therapy

Other key industry trends

  • In terms of revenue, the North America accounted for 34.8% of the global biologics contract manufacturing market in 2024.
  • By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
  • By country, China is the fastest growing regional market and is projected to reach USD 7,472.1 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Biologics Contract Manufacturing Market Companies

Name Profile # Employees HQ Website
Abzena View profile 501-1000 San Diego, California, United States, North America http://abzena.com/
Samsung BioLogics View profile 1001-5000 Incheon, Inch'on-jikhalsi, South Korea, Asia https://www.samsungbiologics.com/
Catalent Inc View profile 17219 14 Schoolhouse Road, Somerset, NJ, United States, 08873 https://www.catalent.com
WuXi Biologics (Cayman) Inc View profile 12740 No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 https://www.wuxibiologics.com
Boehringer Ingelheim View profile 10001+ Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe https://www.boehringer-ingelheim.com/
Merck & Co Inc View profile 72000 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 https://www.merck.com
Eurofins Scientific SE View profile 61798 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 https://www.eurofins.com
Thermo Fisher Scientific Inc View profile 122000 168 Third Avenue, Waltham, MA, United States, 02451 https://www.thermofisher.com
FUJIFILM Holdings Corp View profile 83784 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 http://www.fujifilmholdings.com
Lonza Group Ltd View profile 18000 Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 https://www.lonza.com
AbbVie Inc View profile 50000 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 http://www.abbvieinvestor.com

Global biologics contract manufacturing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract manufacturing market will help companies and investors design strategic landscapes.


Monoclonal antibodies (mabs) was the largest segment with a revenue share of 57.91% in 2024. Horizon Databook has segmented the Global biologics contract manufacturing market based on vaccines, monoclonal antibodies (mabs), recombinant protein, antisense, rnai, & molecular therapy covering the revenue growth of each sub-segment from 2018 to 2030.


  • Global Biologics Contract Manufacturing Product Outlook (Revenue, USD Million, 2018-2030)
    • Vaccines
    • Monoclonal Antibodies (mAbs)
    • Recombinant Protein
    • Antisense, RNAi, & Molecular Therapy
    • Others
  • Global Biologics Contract Manufacturing Indication Outlook (Revenue, USD Million, 2018-2030)
    • Metabolic Diseases
    • Infectious Diseases
    • Neurology
    • Oncology
    • Autoimmune Diseases
    • Cardiovascular Disorders (CVDs)
    • Others

Reasons to subscribe to Global biologics contract manufacturing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Global biologics contract manufacturing market databook

  • Our clientele includes a mix of biologics contract manufacturing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of global-level data and insights on the Global biologics contract manufacturing market , including forecasts for subscribers. This global databook contains high-level insights into Global biologics contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Global biologics contract manufacturing market size, by regions, 2018-2030 (US$M)

Top 10 countries: Biologics contract manufacturing market size, 2024 (US$M)

Global biologics contract manufacturing market share, by product, 2024 & 2030 (%, US$M)

Biologics contract manufacturing market: Opportunity assessment by country

Global biologics contract manufacturing market, by region, 2024 (US$M)

Global biologics contract manufacturing market size, by regions, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online